91.20MXN
38.08 BMXN
223.58 BMXN
482.81 M
About CSL LTD
Sector
Industry
CEO
Paul McKenzie
Website
Headquarters
Melbourne
Employees (FY)
32 K
Founded
1961
ISIN
AU000000CSL8
FIGI
BBG00PGGXGQ1
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CSL/N is 3635.42 MXN — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange CSL LTD stocks are traded under the ticker CSL/N.
CSL LTD is going to release the next earnings report on Aug 13, 2024. Keep track of upcoming events with our Earnings Calendar.
CSL/N stock is 0% volatile and has beta coefficient of 0.47. Check out the list of the most volatile stocks — is CSL LTD there?
CSL/N earnings for the last quarter are 28.06 MXN per share, whereas the estimation was 28.67 MXN resulting in a −2.14% surprise. The estimated earnings for the next quarter are 69.09 MXN per share. See more details about CSL LTD earnings.
CSL LTD revenue for the last quarter amounts to 105.02 B MXN despite the estimated figure of 105.53 B MXN. In the next quarter revenue is expected to reach 134.86 B MXN.
Yes, you can track CSL LTD financials in yearly and quarterly reports right on TradingView.
CSL/N net income for the last quarter is 33.69 B MXN, while the quarter before that showed 10.20 B MXN of net income which accounts for 230.18% change. Track more CSL LTD financial stats to get the full picture.
Today CSL LTD has the market capitalization of 1.47 T, it has decreased by 2.30% over the last week.
CSL LTD dividend yield was 1.31% in 2023, and payout ratio reached 52.45%. The year before the numbers were 1.18% and 47.96% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, CSL/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CSL LTD stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 32.00 K employees. See our rating of the largest employees — is CSL LTD on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CSL LTD technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CSL LTD stock shows the sell signal. See more of CSL LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on CSL LTD future price: according to them, CSL/N price has a max estimate of 3787.36 MXN and a min estimate of 2562.96 MXN. Read a more detailed CSL LTD forecast: see what analysts think of CSL LTD and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CSL LTD EBITDA is 75.14 B MXN, and current EBITDA margin is 28.57%. See more stats in CSL LTD financial statements.